UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	T/
FORM 8-	

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2023

RHYTHM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-38223 (Commission File Number)

46-2159271 (IRS Employer Identification Number)

222 Berkeley Street
12th Floor
Boston, MA 02116
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (857) 264-4280

N/A

(Former name or former address, if changed since last report)

Check the appropriate l	box below if the Forr	n 8-K filing is inten	ded to simultaneou	sly satisfy the fili	ng obligation of th	ne registrant under	any of the
following provisions:							

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
quities registered purposent to Costion 19/h) of the Act	

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Securities registered pursuant to Section 12(b) of the Act:

	Trading	
Title of each class	Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	RYTM	The Nasdaq Stock Market LLC (Nasdaq Global
		Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company \square
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 21, 2023, Rhythm Pharmaceuticals, Inc. (the "Company") held its Annual Meeting of Stockholders. A total of 49,290,096 shares of common stock were present online or represented by proxy at the meeting, representing approximately 86.7% percent of the Company's outstanding common stock as of the April 24, 2023 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2023.

Item 1 - Election of three Class III Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

NOMINEE	Votes FOR	Votes WITHHELD	Broker Non-Votes
Camille L. Bedrosian, M.D.	43,804,864	2,854,511	2,630,721
David W.J. McGirr	42,919,509	3,739,866	2,630,721
David P. Meeker, M.D.	45,045,696	1,613,679	2,630,721

Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.

Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
49,239,432	22,310	28,354	0

Item 3 – Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.

Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes	
38,842,201	1,938,094	5,879,080	2,630,721	

Based on the foregoing votes, Camille L. Bedrosian, M.D., David W.J. McGirr and David P. Meeker, M.D. were elected as Class III Directors, and Items 2 and 3 were approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 22, 2023

RHYTHM PHARMACEUTICALS, INC.

By: /s/ Hunter Smith

Hunter Smith Chief Financial Officer